Bone Care International: Names Charles W. Bishop, Ph.D., as Executive Vice President and Chief Scientific Officer


Middleton, Wisconsin, April 25, 2005–Bone Care International, Inc. (Nasdaq: BCII) today announced the appointment of Charles W. Bishop, PhD, to the position of Executive Vice President and Chief Scientific Officer. Dr. Bishop’s return is designed to drive the company’s performance in new product development and position the company to further increase its growing share of the chronic kidney disease market.

“Charlie is a highly respected scientist with an outstanding reputation and track record in developing novel Vitamin D hormone therapies for the chronic kidney disease market,” said Paul Berns, Bone Care’s President and CEO. “I am confident that his expertise and prior corporate leadership will boost Bone Care’s ability to develop a diverse portfolio of products focused on improving patients’ lives.”

Dr. Bishop rejoins Bone Care from his private pharmaceutical consulting practice based in Madison, Wisconsin. He previously held the following positions at Bone Care: Project Director (1987-1990), Vice President (1990-1996), President and CEO (1996-2001) and Executive Vice President of Research and Development (2001-January 2002). He served as a Director of Bone Care from 1989 until 2001. Prior to joining Bone Care, Dr. Bishop worked as a Group Leader in the Health Care Division of the Procter & Gamble Company. He completed a 4-year postdoctoral fellowship in Vitamin D biochemistry at the University of Wisconsin – Madison, received a PhD from Virginia Tech and an undergraduate degree from the University of Virginia.

Bone Care International ( is a specialty pharmaceutical company engaged in the discovery, development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Our current commercial and therapeutic focus is in nephrology, utilizing Hectorol(R) (doxercalciferol), our novel vitamin D hormone therapy, to treat secondary hyperparathyroidism in patients with moderate to severe chronic kidney disease and end-stage renal disease. In addition to chronic kidney disease, the Company is developing vitamin D hormone therapies to treat hyperproliferative disorders such as cancer and psoriasis.